Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Linrodostat mesylate by Bristol-Myers Squibb for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Linrodostat mesylate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According...